FLEX007

Flex007-Apr2019

Issue link: https://iconnect007.uberflip.com/i/1108006

Contents of this Issue

Navigation

Page 19 of 83

20 FLEX007 MAGAZINE I APRIL 2019 on dialysis; they go to dialysis treatment three times a week. Then, we're looking at conges- tive heart failure or heart failure at large, since 40% of dialysis patients are diagnosed with heart failure. These are two very big markets in need of innovation, especially in supporting the patients' lives outside of the clinic. Goldman: Today, we're here to talk about the topic for this issue, which is "From Design Through Final Product." Our thought was to follow a product through from the design—the very beginning—through all of your concerns and what happens to make that product a real- ity. Let's jump in at the design stage and talk about how everything worked out with Dave and Rich from Lenthor's perspective. I know the end was good, but what happened in between? David Moody: Tony, if you could give us a brief description of what determined the ultimate solution, that would be great. For example, it had to be a rigid-flex design from the stand- point of what you were trying to accomplish when you were all sitting around the table with a napkin trying to figure out what to do. Flannery: It's funny. We're all going to sit down and write our memoirs about this com- pany someday. GraftWorx has been around for about six and a half years, and we first cut our teeth on trying to bring a product to market on a monitoring system for peripheral arterial dis- ease. And there's a long, convoluted history that goes beyond the scope of this conversa- tion. What we ended up realizing was there was a tremendous opportunity to do this, and we'd get to market faster in the wearable space. It's no secret or surprise that there's a tremen- dous opportunity in medicine to generate data that can make a huge difference in a clinical outcome. As Amit was describing, we're trying to generate quality data that goes back to the clinic and has a positive impact on managing patients with a very difficult disease, end-stage renal disease. We wanted to design something that fits into a patient's lifestyle with very little impact on their lives. In terms of conveying what we're trying to do, this is something that sits on your skin, such as a small, smart bandage. We wanted it to move with you and be flexible, comfortable, light, and forgettable. But at the same time, it's a very sophisticated device. We have 11 dif- ferent sensor data streams acquired during a reading. There is encryption that goes on so that we're HIPAA-compliant in terms of how we store and transmit patient data. There is a tremendous optimization that went into power management so that our device lasts as long as it does on the skin, and this data is pulled into our cloud via a medical data relay (Figure 1). Figure 1: The GraftWorx end-to-end data path. Results from patient monitoring are transmitted via a semi-custom Bluetooth link to our B2H data bridge. Data is transmitted over a cellular IoT network to the Cloud where, after authentication, data is processed and alerts generated. Data and alerts are available to clinicians as part of their standard clinical workflow.

Articles in this issue

Archives of this issue

view archives of FLEX007 - Flex007-Apr2019